Oblique, Therapeutics

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

Published on 08/07/2025 at 18:05 | prnewswire.co.uk

Oblique Therapeutics AB Sweden

View original content:https://www.prnewswire.co.uk/news-releases/oblique-therapeutics-has-entered-a-research-collaboration-agreement-with-eli-lilly-and-company-to-apply-the-abiprot-technology-to-generate-antibodies-to-a-high-value-target-302228552.html

en | CA7609751028 | OBLIQUE | boerse | 67972877 |